SanegeneBio has entered into a $1.5bn global licensing agreement with Genentech, part of the Roche Group, for one of its RNAi ...
Pharmaceutical Technology on MSN
Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies
Qilu Pharmaceutical will oversee subsequent development and commercialisation activities.
Advances in device technologies and component innovations, such as Datwyler’s NeoFlex™ plungers, facilitate home-based ...
Dr. Stacy Lindborg is president and CEO of IMUNON, a clinical-stage company in phase 3 development with a lead DNA-mediated immunotherapy for advanced ovarian cancer. Dr. Lindborg has worked in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results